Metformin versus levonorgestrel-releasing intrauterine system in the management of endometrial hyperplasia: a randomized clinical trial
Abstract Background Endometrial hyperplasia is one of the common causes of bleeding in perimenopausal women. Variable treatment options aim to induce regression. The current study evaluated the regression rate of endometrial hyperplasia after treatment with levonorgestrel intrauterine system (LNG- I...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2023-08-01
|
| Series: | Middle East Fertility Society Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43043-023-00145-7 |
| _version_ | 1827635555463069696 |
|---|---|
| author | Omima T. Taha Mohammed M. Abd-Elgelil Eman A. Kishk Mohammed Shaaban Rasha E. Khamees |
| author_facet | Omima T. Taha Mohammed M. Abd-Elgelil Eman A. Kishk Mohammed Shaaban Rasha E. Khamees |
| author_sort | Omima T. Taha |
| collection | DOAJ |
| description | Abstract Background Endometrial hyperplasia is one of the common causes of bleeding in perimenopausal women. Variable treatment options aim to induce regression. The current study evaluated the regression rate of endometrial hyperplasia after treatment with levonorgestrel intrauterine system (LNG- IUS) versus Metformin. Methods This randomized clinical trial was conducted at the obstetrics and gynecology department of Suez Canal University hospital. We recruited women diagnosed with endometrial hyperplasia without atypia. Patients were allocated into two groups. Group one included patients treated with levonorgestrel-releasing intrauterine system and group two treated with Metformin. The rate of regression of hyperplasia in both groups after six months of intervention was the main outcome measure. Results Significant regression of hyperplasia was noted in the LNG-IUS group (96% versus 64%, p-value 0.009). There was a significant decrease in the endometrial thickness after treatment in both groups (17.65 ± 4.62 and 5.3 ± 2.01 in the LNG- IUS with a p-value < 0.001) (19.57 ± 6.84 and 11.22 ± 7.51 in the metformin group with a p-value < 0.001). Factors that correlated with the Δ endometrial thickness included parity in the LNG- IUS group (p-value 0.019) and age and BMI in the metformin group (p-value 0.043 and 0.004 respectively). Conclusion Metformin had a regressive effect on endometrial hyperplasia; however, it was not significant as that achieved with the levonorgestrel intrauterine system. Trial registrations PACTR201908498370196. Date of registration: 21/8/2019. Date of first patient enrollment: 25/8/2019. URL: https://pactr.samrc.ac.za/Researcher/TrialRegister.aspx?TrialID=9335 |
| first_indexed | 2024-03-09T15:28:17Z |
| format | Article |
| id | doaj.art-6efcdb3656c544258b0bbe6b9b1d5251 |
| institution | Directory Open Access Journal |
| issn | 2090-3251 |
| language | English |
| last_indexed | 2024-03-09T15:28:17Z |
| publishDate | 2023-08-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Middle East Fertility Society Journal |
| spelling | doaj.art-6efcdb3656c544258b0bbe6b9b1d52512023-11-26T12:23:27ZengSpringerOpenMiddle East Fertility Society Journal2090-32512023-08-012811710.1186/s43043-023-00145-7Metformin versus levonorgestrel-releasing intrauterine system in the management of endometrial hyperplasia: a randomized clinical trialOmima T. Taha0Mohammed M. Abd-Elgelil1Eman A. Kishk2Mohammed Shaaban3Rasha E. Khamees4Department of Obstetrics and Gynecology, Faculty of Medicine, Suez Canal UniversityDepartment of Obstetrics and Gynecology, Faculty of Medicine, Suez Canal UniversityDepartment of Obstetrics and Gynecology, Faculty of Medicine, Suez Canal UniversityDepartment of Obstetrics and Gynecology, Faculty of Medicine, Suez Canal UniversityDepartment of Obstetrics and Gynecology, Faculty of Medicine, Suez Canal UniversityAbstract Background Endometrial hyperplasia is one of the common causes of bleeding in perimenopausal women. Variable treatment options aim to induce regression. The current study evaluated the regression rate of endometrial hyperplasia after treatment with levonorgestrel intrauterine system (LNG- IUS) versus Metformin. Methods This randomized clinical trial was conducted at the obstetrics and gynecology department of Suez Canal University hospital. We recruited women diagnosed with endometrial hyperplasia without atypia. Patients were allocated into two groups. Group one included patients treated with levonorgestrel-releasing intrauterine system and group two treated with Metformin. The rate of regression of hyperplasia in both groups after six months of intervention was the main outcome measure. Results Significant regression of hyperplasia was noted in the LNG-IUS group (96% versus 64%, p-value 0.009). There was a significant decrease in the endometrial thickness after treatment in both groups (17.65 ± 4.62 and 5.3 ± 2.01 in the LNG- IUS with a p-value < 0.001) (19.57 ± 6.84 and 11.22 ± 7.51 in the metformin group with a p-value < 0.001). Factors that correlated with the Δ endometrial thickness included parity in the LNG- IUS group (p-value 0.019) and age and BMI in the metformin group (p-value 0.043 and 0.004 respectively). Conclusion Metformin had a regressive effect on endometrial hyperplasia; however, it was not significant as that achieved with the levonorgestrel intrauterine system. Trial registrations PACTR201908498370196. Date of registration: 21/8/2019. Date of first patient enrollment: 25/8/2019. URL: https://pactr.samrc.ac.za/Researcher/TrialRegister.aspx?TrialID=9335https://doi.org/10.1186/s43043-023-00145-7Endometrial hyperplasiaLevonorgestrel- intrauterine systemMetformin |
| spellingShingle | Omima T. Taha Mohammed M. Abd-Elgelil Eman A. Kishk Mohammed Shaaban Rasha E. Khamees Metformin versus levonorgestrel-releasing intrauterine system in the management of endometrial hyperplasia: a randomized clinical trial Middle East Fertility Society Journal Endometrial hyperplasia Levonorgestrel- intrauterine system Metformin |
| title | Metformin versus levonorgestrel-releasing intrauterine system in the management of endometrial hyperplasia: a randomized clinical trial |
| title_full | Metformin versus levonorgestrel-releasing intrauterine system in the management of endometrial hyperplasia: a randomized clinical trial |
| title_fullStr | Metformin versus levonorgestrel-releasing intrauterine system in the management of endometrial hyperplasia: a randomized clinical trial |
| title_full_unstemmed | Metformin versus levonorgestrel-releasing intrauterine system in the management of endometrial hyperplasia: a randomized clinical trial |
| title_short | Metformin versus levonorgestrel-releasing intrauterine system in the management of endometrial hyperplasia: a randomized clinical trial |
| title_sort | metformin versus levonorgestrel releasing intrauterine system in the management of endometrial hyperplasia a randomized clinical trial |
| topic | Endometrial hyperplasia Levonorgestrel- intrauterine system Metformin |
| url | https://doi.org/10.1186/s43043-023-00145-7 |
| work_keys_str_mv | AT omimattaha metforminversuslevonorgestrelreleasingintrauterinesysteminthemanagementofendometrialhyperplasiaarandomizedclinicaltrial AT mohammedmabdelgelil metforminversuslevonorgestrelreleasingintrauterinesysteminthemanagementofendometrialhyperplasiaarandomizedclinicaltrial AT emanakishk metforminversuslevonorgestrelreleasingintrauterinesysteminthemanagementofendometrialhyperplasiaarandomizedclinicaltrial AT mohammedshaaban metforminversuslevonorgestrelreleasingintrauterinesysteminthemanagementofendometrialhyperplasiaarandomizedclinicaltrial AT rashaekhamees metforminversuslevonorgestrelreleasingintrauterinesysteminthemanagementofendometrialhyperplasiaarandomizedclinicaltrial |